Thus, this study encourages further preclinical and eventually clinical trials with HDAC and BET inhibitors in combination with cisplatin to overcome cisplatin resistance and foster treatment efficacy in bladder cancer. This evidence concerns the gene DNER and urinary bladder carcinoma.